FDA Rejects Cancer-Causing Weight Loss Drug

U.S. health officials have rejected Arena Pharmaceuticals’ experimental obesity pill, citing cancer risks. The FDA said the risks outweighed the "marginal" effectiveness of the drug.

Arena had hoped that the drug would be the first new U.S. prescription weight-loss drug in more than a decade. But the FDA's outside advisers urged the agency to reject the pill based on the tumors it induced in rats.

According to Reuters:

“[The] announcement is the latest in a string of bad news for U.S. diet drugs. Abbott Laboratories' controversial Meridia was pulled off the market earlier this month, leaving few alternatives. FDA panelists in July also rejected a potential rival from Vivus Inc.”

+ Sources and References
Post your comment
Click Here and be the first to comment on this article